Q3 2022 XPOVIO sales up 20% YoY; net loss narrows to $0.45/share; guidance reaffirmed

Karyopharm Therapeutics Inc.

2022-Q3 EPS reported -$1.60 revenue$123,494,000

Total revenue $36.1M (-4% YoY); XPOVIO net product revenue $32.0M (+20% YoY).
Net loss $36.3M ($0.45 per share) vs $51.8M ($0.69) in Q3 2021; cash $150.1M.
Reaffirmed FY2022 guidance: total revenue $155-165M, XPOVIO $120-130M.
Initiated Phase 3 selinexor maintenance in TP53 wild-type endometrial cancer; topline 2024.
Phase 1 selinexor+ruxolitinib in myelofibrosis shows SVR35 at 79% at week 12; updated data at ASH.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Karyopharm Therapeutics Inc. reported the quarter ended September 30, 2022 results: revenue $36.1 Million. Guidance reaffirmed.

Period: the quarter ended September 30, 2022
Revenue: $36.1 Million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Karyopharm Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress – Achieved Third Quarter 2022 Total Revenue of $36.1 Million

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Karyopharm Therapeutics Inc. reported full year 2022 results: revenue $155 Million to $165 Million. Guidance reaffirmed.

Period: full year 2022
Revenue: $155 Million to $165 Million
Guidance: reaffirmed
Result: guidance update

Exact text from the filing

Company Re-Affirms Full Year 2022 XPOVIO Net Product Revenue Guidance of $120 Million to $130 Million, Total Revenue Guidance of $155 Million to $165 Million and Cash Runway into Early 2024

View on SEC.gov

6 earnings releases filed in the last 30 days. Browse all earnings releases →

Karyopharm Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-276891

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.